TABLE 2.

Frequency of antigen-specific CD8⁺ T cells recognizing the PR82V_76-84 and/or PR82A_76-84 peptide in the HIV-1 protease gene^a

Patient	Amino acid at position 82	% IFN-γ-producing CD8+ T cells		HLA-A2
		PR82V76-84	PR82A76-84
SNC		<0.050	<0.050	+
SNC		<0.050	<0.050	+
3005	Val	<0.050	<0.050	−
3085	Val	<0.050	<0.050	−
3148	Val	<0.050	<0.050	−
3152	Val	<0.050	<0.050	−
2004	Ala	<0.050	<0.050	−
3004	Ala	<0.050	<0.050	−
3025	Ala	<0.050	<0.050	−
3028	Ala/Val	<0.050	<0.050	−
3047	Ala	<0.050	<0.050	−
3062	Ala	<0.050	<0.050	−
3071	Ala	<0.050	<0.050	−
3072	Ala	<0.050	<0.050	−
3075	Ala	<0.050	<0.050	−
3102	Ala	<0.050	<0.050	−
2081	Val	0.166	<0.050	+
3011	Val	0.204	<0.050	+
3013	Val	0.070	<0.050	+
3043	Val	<0.050	<0.050	+
3057	Val	0.056	<0.050	+
3151	Val	0.104	0.075	+
3153	Val	0.280	0.100	+
3156	Val	0.330	0.180	+
3012	Ala	<0.050	<0.050	+
3023	Ala	0.130	0.360	+
3037	Ala	<0.050	0.061	+
3040	Ala	0.054	0.123	+
3050	Ala	<0.050	<0.050	+
3084	Ala/Val	<0.050	<0.050	+
3088	Ala	<0.050	<0.050	+

^aCells gated on IFN-γ-producing CD3⁺ CD8⁺ CD4⁻ T cells were detected by intracellular CFC. The proportion of patients with the V82A mutation is greater in the group of HLA-A2-negative patients than in the HLA-A2-positive group, but the difference does not reach statistical significance (P = 0.17; chi square test). Levels above 0.05 with the background subtracted (mean background + 2SD = 0.05) are considered positive. SNC, seronegative control; Ala/Val, presence of viral sequences with both Ala and Val at position 82.